Clinical Research Directory

Inclusion Criteria: * Patients with histologically confirmed invasive adenocarcinoma of the breast. * Triple negative breast cancer: hormone receptor negative (ER \< 10% and PgR \< 10%) and HER2 negative (IHC 0/1+ or ISH non-amplified), as defined by the local pathology laboratory. * Clinical stage at presentation: T1-4, N0-3, M0, with indications for neoadjuvant chemotherapy. * Patient must have received platinum and taxanes neoadjuvant chemotherapy for at least 4 cycles and no tumor progression occurred. * Patients should have undergone adequate tumor excision in the breast and lymph nodes after neoadjuvant chemotherapy. * Residual invasive disease must be ≥1cm in the breast, and/or have positive axillary lymph nodes observed on pathologic exam after neoadjuvant chemotherapy. * ECOG Performance Status: 0-1. * Patients without severe heart, lung, liver and kidney disease. * Adequate hematologic and end-organ function. * No more than 6 weeks may elapse between definitive breast surgery and randomization. Exclusion Criteria: * Previous neoadjuvant chemotherapy with anthracycline or other drugs (except platinum and taxanes). * Previous neoadjuvant chemotherapy with platinum or taxanes alone. * Patients have received other adjuvant therapy. * Comprehensive medical examinations have revealed distant metastases before randomization. * Patients who are not suitable for anthracycline evaluated by investigators. * Prior history of other malignancy (except carcinoma in situ).